Corteva (CTVA) Q1 FY26 earnings call: guidance and Q&A

Where should investors focus and be most enthusiastic about Corteva's trajectory over the next few years, on Seed or CP?

Chuck pointed to two big value levers — deploying leading technology and disciplined cost productivity (prior 3-year plan of $1B cost, trending ahead). He stacked the CP pipeline (7 new AIs plus biologicals and a first biocontrol over the next decade) and the Seed licensing story (first royalty-positive year, ~$1B incremental corn/soy licensing revenue over a decade, plus a ~$1B hybrid wheat opportunity and gene-editing expansion beyond corn/soy) as the growth drivers, calling Vylor a 'classic growth compounder.'

“this is the first year that we're going to be royalty positive, and that's new information for this morning. And we were thinking we would be royalty neutral.”

asked by Christopher Parkinson · answered by Charles Magro

Is the crop chemicals supply/demand environment starting to improve out of China, and when does it show up in results?

Chuck reaffirmed a return to modest low-single-digit industry growth in 2026. Higher energy/oil is inflating AI production costs in India and China, driving price increases on certain AIs; China's reinstated VAT export controls add ~8% on certain AIs; and there is a slight, recent (March data) slowdown in Chinese exports into Brazil. He characterized the 2026 impact as minimal (Brazil holds enough inventory for most of the year) but a positive sign for late-2026/2027.

“China put also some export controls of VAT back on, which is also causing, I think it's about an 8% price increase for certain amounts of AI.”

asked by Vincent Andrews · answered by Charles Magro

How much earnings moved from Q4 into Q1, and what are the better/worse buckets versus the February bridge?

David said the shifted month was already in the original bridge, so results are broadly in line, with H1 now up more than the ~7% originally modeled. Puts and takes are minor on a $4B+ base: currency and the royalty journey a bit favorable, tariffs slightly favorable, and tax likely at the lower end, offset by an ~$40M Iran/oil-inflation headwind mainly in the back half.

“these are pretty minor puts and takes when you think of a $4-plus billion kind of an outlook number.”

asked by Joel Jackson · answered by David Johnson

Why were corn volumes up 7% and soybeans down, and how does the ~$700M higher Q1 cash use and $1.5B pension break down?

Judd attributed the corn/soy split to timing — North America is a first-half business and some corn volume shifted out of Q4 2025; the soybean order book is solid with no red flags. David said the ~$700M Q1 swing was largely the Bayer agreement payout; underlying conversion stays 40-50% (45% midpoint); and the $1.5B pension is pretax with ~$290M of tax savings.

“the biggest impact of that is the Bayer agreement that we paid out in Q1... the business itself is still right in that 40% to 50%, 45% at the midpoint conversion rate.”

asked by Jeffrey Zekauskas · answered by David Johnson

Why hold Brazil corn acres flat given high nitrogen prices, and how much working-capital/credit risk are you willing to take in Latin America?

Chuck explained safrinha is a double-crop after soybeans, and with high fertilizer prices Corteva expects flat (not expanded) second-corn area this year, with any corn-to-soy shift far smaller than in North America. David leaned on Corteva's #1 barter program and strategic customer-by-customer credit, noting bad debt was ~25% of the ~$100M Q1 SG&A increase but past-due as a percent of sales is in line or slightly favorable.

“when you look at our SG&A being up roughly $100 million in this first quarter... about 25% of that was bad debt.”

asked by Patrick Fischer (Duffy Fisher) · answered by David Johnson

Where does the H2 step-up in CP volume come from by product and region, versus the market?

Robert King said the acceleration is primarily Latin America — more acres in production, growing biologicals (Nutricia and Blue N nitrogen generator, an alternative to high-priced ammonia/urea), continued spinosyn growth, and rising tropical resistance pressure — driving double-digit CP growth in the back half.

“between biologicals in Latin America... the growth that we saw in the first quarter of spinosyn... That's really what's driving us in the second half to get the double-digit growth for Crop Protection.”

asked by Lucas Beaumont (for Joshua Spector) · answered by Robert King

How is the global biofuels shift affecting demand, and is there incremental interest in Corteva's biofuel cropping platform?

Chuck cited record biofuel demand — Brazil raising ethanol blends and using more domestic corn, Southeast Asia targeting aviation fuel, and a possible US year-round E15 that could consume up to ~15% more of the US corn crop. Judd detailed ~100,000 acres of a winter oilseed system with Bunge and Chevron for SAF (>90% farmer retention), expanding to >400,000 acres next year, plus a new 50/50 BP JV in Latin America for mustard/oilseeds with crop going in the ground in 2027.

“our view would be if we get to E15 it could consume up to another 15% of the U.S. corn crop.”

asked by Kristen Owen · answered by Charles Magro

What operational milestones remain before the spin, and how are you attacking dissynergies pre- versus post-spin?

Chuck said there have been no surprises; Q4 timing feels solid, with milestones done (Luke Kissam as CEO, both leadership teams, Form 10, Vylor name) and headquarters, public filing, boards and capital structure ahead. David split the ~$100M dissynergies into outside spend (public-company costs, trending as expected) and organizational structure, where an already-implemented ~$80M Q1 restructuring to right-size the org drove the favorability.

“we have now implemented a restructuring program, which we talked about, about $80 million that we took hit in Q1, that is all in effect to get these two work structures appropriate for both businesses.”

asked by Kevin McCarthy · answered by David Johnson